Blue Horseshoe Stocks: NVAX, NQ & More

Novavax, Inc. NVAX 

NVAX is the latest Ebola-related stock to catch our eye, and while the initial fear that was driving a lot of these plays has calmed as people realize that the virus doesn’t exactly spread like wildfire, there is much being made of efforts to find a working vaccine and NVAX is attempting to answer that call.

The company announced today that it had presented at the 8th Vaccine and ISV Conference in Philadelphia on Sunday on what was called the first Ebola Vaccine Candidate based on the 2014 Guinea strain that caused the current outbreak in West Africa.

The company said it expects to begin Phase I testing by December, so we’re going to add NVAX to our watchlists for the time being. Additionally, the stock is gapping up to the tune of 10% here in the premarket, and the chart appears to have the possibility of a Golden Cross in the making.


NQ Mobile, Inc. NQ

This is a play we’ve tracked continuously since late this spring. After witnessing a nice move back in July from the low $4-range to the mid-$7’s, the stock had been under general consolidation until it found and bounced off of support about 6 weeks ago. It has made a nice steady recovery from that point on, and is gaining more traction this morning as it gaps up in the premarket on the heels of a PR.

The mobile security has just company submitted the necessary back-filings to once again become fully compliant, and no anomalies or adverse findings were uncovered, which adds another dimension to this play.

We also like the space NQ operates in- with mobile devices permeating every aspect of the current culture, the need for mobile security services such as those provided by NQ only stands to grow in the future.


Side Note:
PTIE, DRRX (Two that are gapping down significantly; we will want to watch for an eventual bounce)


Extended Watchlist:
ISR, AEZS, TSEM, CEMI,

DRRX, PPHM & Extended Watchlist

Durect Corp. DRRX

We are putting DRRX on our radar this morning; it has recently come off of a bottom, and is gaining some momentum as it begins its recovery. Prior to May, this pharmaceutical play was trading at a base level well above 1.20, before seeing a large spike followed by a sharp dropoff. If DRRX can break through resistance at the 50DMA & 200DMA there’s a chance it could come up to fill that gap on the chart. A return to previous levels from here could yield gains of up to 20%

In addition to a connection with pharma giant Pfizer, the company has also gotten FDA acceptance of a New Drug Application (NDA) as outlined in yesterday’s PR:

CUPERTINO, Calif., June 20, 2013 /PRNewswire via COMTEX/ — DURECT Corporation (Nasdaq: DRRX) today announced that the New Drug Application (NDA) for the investigational product POSIDUR (SABER-Bupivacaine) has been accepted by the U.S. Food and Drug Administration (FDA) indicating that the application is sufficiently complete to permit a substantive review. POSIDUR is a post-operative pain relief depot that utilizes DURECT’s patented SABER technology to deliver bupivacaine and is designed to provide up to three days of pain relief after surgery. DURECT submitted the NDA as a 505(b)(2) application. The Prescription Drug User Fee Act (PDUFA) goal date (the date the FDA expects to complete its review of the NDA) has been confirmed as February 12, 2014.


Peregrine Pharmaceuticals, Inc. PPHM

Speaking of pharmaceutical plays, one of the stocks that we continuously monitor is PPHM. Many of you will remember back in May when the stock provided us with some serious opportunities for profit.

Recently PPHM has been in a marked downtrend, and as you can see on the chart below, indicators seem to confirm this fact. We are going to want to put this one on bottom watch over the next several sessions, as the resulting bounce/s could be significant.


Side Note: 

Since Ben Bernanke’s recent comments regarding the Fed’s upcoming tapering of quantitative easing measures, markets have been in freefall. If no reversal occurs and that remains the overall trend, we are going to want to keep an eye on SPY Puts, VIX/VXX Calls.


Extended Watchlist:
ONCI, ONCO, LIVE, KERX, MSTX